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Background and PurposezzThe World Health Organization (WHO) has classified thymic 
carcinoma and other thymomas (types A, AB, and B) as different neoplasms. Myasthenia gravis 
(MG) is an early sign of thymoma and theoretically does not accompany thymic carcinoma; 
however, cases of thymic carcinoma with MG have been reported. Whether thymic carcinoma 
can accompany MG has yet to be established.
MethodszzThe medical records of patients who underwent thymectomy for MG between 1990 
and 2011 in a single hospital were reviewed. All cases with the diagnostic code of “thymic carci-
noma” or “thymoma type C” (old terminology) were selected. A pathologist re-reviewed the 
pathologic specimens using the new WHO criteria. The rate of thymic carcinoma among these 
MG patients was then calculated.
ResultszzA total of 81 patients with MG had thymic tumors, 10 of whom had thymic carcino-
mas or thymoma type C. Seven cases of well-differentiated thymic carcinomas (type B3) were 
excluded, leaving three (3.7%) cases of thymic carcinoma with MG. All three of these cases 
were type B3 thymoma with a focal squamous cell carcinoma component that was very small 
and well demarcated. In addition, two out of the three tumors were found to be at an early clini-
cal stage. All of the cases survived without recurrence over follow-up periods of at least 5 years.
ConclusionszzThymic carcinoma transformation from thymoma can occur during the early 
stages of thymoma. The association of this condition with MG is not as rare as was previously 
thought. Thymic carcinomas accompanying MG had a predominant B3 thymoma component 
with a focal thymic carcinoma area (squamous cell carcinoma).
Key Wordszz thymoma, thymic carcinoma, thymic squamous cell carcinoma,  
myasthenia gravis, thymectomy.
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INTRODUCTION
Early thymectomy is the standard treatment modality for myasthenia gravis (MG) patients 
with thymoma. MG patients have reduced pulmonary function, and surgery is often limited 
to using muscle relaxants and antibiotics. Therefore, minimally invasive techniques are more 
commonly used to treat MG.1-3 However, the basis for the use of these minimally invasive 
techniques is the absence of thymic carcinoma, because when it is present, complete resec-
tion is important for survival.4
Thymomas [World Health Organization (WHO) types A, AB, and B] are neoplasms arising 
from or exhibiting differentiation toward thymic epithelial cells; they also exhibit a nonneo-
plastic lymphoid structure. Their malignant potential ranges from absent to low. Collabora-
tion between the dysfunctional neoplastic thymic structure and the nonneoplastic lym-
phoid structure induces autoimmune diseases such as MG. On the other hand, thymic 
carcinomas are malignant epithelial tumors with overt cytologic atypia, almost invariable in-
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vasiveness, and a lack of “organotypic” (thymus-like) fea-
tures.5 MG has been most commonly associated with WHO 
type A, AB, or B thymoma, but not thymic carcinoma.6-10
While the WHO has classified thymoma and thymic carci-
noma as different tumor types, it has been shown that thymic 
carcinomas (which have very poor prognoses) can actually 
Fig. 1. Pathologic findings of case 2. Focal thymic carcinoma with an abundant thymoma (thymoma type B3) component. Low-power view show-
ing a multinodular mass with extension to the peritumoral fat tissue [circle; hematoxylin-eosin stain (H-E); magnification, ×12] (A). The tumor is 
composed of abundant type B3 tissue (B: H-E; magnification, ×40; C: H-E, magnification, ×400) (B, C) and a focal thymic carcinoma component 
(squamous cell carcinoma) in the circled area (H-E; magnification, ×400) (D). Strong immunoreactivity for p63, a squamous cell differentiation 
marker, is found in the thymic carcinoma area (p63 immunostaining; magnification, ×400) (E). There is no p63 reactivity in the conventional thy-
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arise after the development of the thymoma.5,11 Theoretically, 
thymic carcinoma can accompany MG after a sufficient peri-
od. MG is an early and easily detectable sign of a thymoma, 
and therefore thymoma with MG is generally detected at an 
early stage and has a better prognosis than thymoma without 
MG.9 Early thymectomy is the standard treatment of MG with 
thymoma. Whether or not thymic carcinoma can arise in thy-
moma with MG has yet to be established.
METHODS
The medical records of patients who underwent thymectomy 
between January 1990 and December 2011 at the Yonsei Med-
ical Health System, Seoul, Korea were reviewed. All cases with 
a pathologic diagnostic code of “thymic carcinoma” or “WHO 
type C” were selected. From these, all cases with MG were se-
lected. MG was diagnosed by a positive repetitive nerve stim-
ulation study and/or the presence of anti-acetylcholine-recep-
tor antibody. Each case was reviewed and reclassified according 
to the 2004 WHO classification.5
The study protocol was reviewed and approved by the In-
stitutional Review Board (IRB No. 2014-08-114). Informed 
consent was waived by the board due to the retrospective na-
ture of the study.
RESULTS
A total of 297 patients had undergone thymectomy due to 
thymic tumor during the test period, of whom 29 (9.8%) were 
classified as having thymic carcinoma. Eighty-one patients 
were found to have a thymic tumor with MG, 10 of which were 
classified as either thymic carcinoma or thymoma type C. Af-
ter applying the new WHO criteria, seven of the ten cases were 
reclassified as having well-differentiated thymic carcinoma 
(WHO type B3). Three cases (3.7%) of thymic carcinoma 
were found (one man and two women; mean age, 47.3 years).
All three cases of thymic carcinoma had a predominant B3 
or B2 thymoma area with a focal, well-demarcated squamous 
cell carcinoma area and overt cytologic atypia; two patients 
had a type B3 thymoma and the other patient had a type 
B2+B3 thymoma (a thymic carcinoma portion was seen in 
the B3 area). Thymic carcinoma portions were clearly identi-
fiable from thymoma portions, and their areas were much 
smaller than that of the thymoma (Fig. 1A-D). The thymic 
carcinoma area exhibited strong immunoreactivity for p63, 
which is a squamous cell differentiation marker; the conven-
tional thymoma B3 tissue was not p63 immunoreactive (Fig. 
1E and F).
All three patients are currently still alive and without recur-
rence, after follow-up periods of 5, 10, and 22 years. The 
pathologic findings are summarized in Table 1.
DISCUSSION
While no de novo thymic carcinomas were found in the pres-
ent study, a small (3.7%) portion of thymomas with MG had 
a mixed thymic carcinoma portion. Previous studies and other 
reports have clearly established that large thymic carcinomas 
with poor prognoses can arise from a preexisting thymoma.11,12
The point at which transformation to thymic carcinoma 
occurs is unknown. Two previously reported cases of thymic 
squamous cell carcinoma developed from thymomas after 10 
and 14 years;12 it was unknown whether these thymic carci-
nomas were able to develop during the earlier stages of the 
thymoma. A recent study found that a large portion of a thy-
moma exhibited mixed histology findings.13 Moreover, addi-
tional research has shown that type B2 thymomas are geneti-
cally related to type B3 thymomas, in line with the frequent 
histologic observation of combinations of type B2 and B3 ar-
eas in the same tumor.14,15 It has further been suggested that 
some type B2 thymomas are precursor lesions of type B3 tu-
mors.15 As a part of the thymic carcinoma, thymic squamous 
cell carcinomas frequently show gains of chromosomes 1q, 
17q, and 18, and the loss of chromosomes 3p, 6, 16q, and 
17p.16 Apart from the “thymic stemness” alteration on chro-
mosome 6q25, thymic squamous cell carcinomas share other 











1 Female/67 years 3.2 IU 19 days
Thymoma, predominantly type B3  
  with a focal area of carcinoma of 
  squamous cell type
4 B3
2 Male/31 years 11.3 IU 10 days
Focal squamous cell carcinoma  
  with type B3+B2 thymoma
2B B3
3 Female/44 years 2.6 IU 17 days
Squamous cell carcinoma with  
  type B3 thymoma
2B B3
AntiAchR Ab: anti-acetylcholine-receptor antibody.
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similarities with type B3 thymomas, namely gain of chromo-
some 1q and loss of chromosome 6. Apart from these simi-
larities, they are genetically distinct from thymomas, justifying 
their listing as a separate entity in the WHO classification.15,17,18
A squamous cell carcinoma can theoretically develop inside 
a B3 thymoma. However, any type of thymic carcinoma can 
develop within all types of thymoma.11 We believe that this 
phenomenon is due to the long period before detection of 
malignant transformation. In addition, thymic carcinomas 
have been shown to develop in the necrotic portion of a thy-
moma.11 All of the thymic carcinomas in our case were squa-
mous cell carcinomas and were accompanied by B3 thymomas.
The standard surgical technique for treating thymic carci-
nomas is median sternotomy with complete thymectomy and 
removal of all surrounding mediastinal fat.19 There are no 
published data on the use of minimally invasive surgery for 
thymic carcinoma.20
In conclusion, thymoma with MG had a thymic carcinoma 
component; this thymic carcinoma portion was small and lo-
calized within the thymoma in these patients.
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